IHL files an International patent application for IHL-42X based on interim analysis of the data from the phase 2b trial. The results were included in the patent application to support the claims.
And, they received ethics approval to commence an open label extension study for people who have experienced a benefit from IHL-42X.
December 2021
Dosing completed and the company immediately commenced preparation for a pre-IND meeting with FDA, targeting Q1, 2022.
Any of this sound negative to you? It sounds extremely positive to me.
IHL Price at posting:
45.5¢ Sentiment: Buy Disclosure: Held
